|
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN PHENAZINE, PHENDIMETRAZINE TARTRATE PHENAZINE-35, PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE PHENERGAN W/ CODEINE, CODEINE...
|
|
|
chrmscat.p65 page 1
author: cxm9300
|
|
|
http://www.freseniushc.com/product/April_1_2001_Update.pdf
April 1 2001 Update Addendum A. Update of Calendar Year 2001 Hospital Outpatient Payment Rates and Coinsurance Amounts Effective April 1, 2001 National Minimum Status Relative Payment Unadjusted Unadjusted APC Group Title Indicator Weight Rate Coinsurance Coinsurance 0001 Photochemotherapy ...
|
|
|
Palatin Technologies - The Leader in Melanocortin-based Therapeutics
To address this issue, Tyco International today brought together a broad panel of medical and economic experts to outline the problem and describe how a breakthrough imaging agent, NeutroSpec(TM) [Technetium (99m Tc) fanolesomab], can help reduce the human pain and economic cost of misdiagnosed appendicitis.
NeutroSpec includes a technetium-labeled anti-CD...
|
|
|
Palatin Technologies - The Leader in Melanocortin-based Therapeutics
(Amex: PTN - News) today announced that they have extended their marketing agreement for Palatin's infection imaging agent, NeutroSpec(TM) (Technetium Tc-99m fanolesomab), to include exclusive marketing and distribution rights in Europe.
- ### - - Overview Press Releases Event Calendar Webcasts SEC Filings Analyst Coverage Corporate Governance Information Request...
|
|
|
Palatin Technologies - The Leader in Melanocortin-based Therapeutics
Rapid diagnosis of pedal osteomyelitis in diabetics with a Technetium-99m-labeled monoclonal antigranulocyte antibody.
Tc-99m anti-CD 15 neutrophil monoclonal antibody (NeutroSpec®) scan for diagnosis of equivocal appendicitis: Clinical evaluation of safety, efficacy and patient management.
Radiation dosimetry of a 99m Tc-labeled IgM...
|
|
|
PII: S0969-8051(01)00218-9 page 5
|
|
|
PII: S0969-8051(01)00218-9 page 4
|
|
|
doi:10.1016/S0969-8051(03)00028-3 page 7
|
|
|
doi:10.1016/S0969-8051(03)00028-3 page 2
|
|
|
http://www.neoprobe.com/UCSD/ASOwallace2003.pdf page 8
|
|
|
neo2000 Manual DOC0755 Rev D
° Radionuclide is automatically set to Technetium 99m, and this indicator lights up.
Select a radionuclide different from Technetium 99m.
If there are no system errors and a probe is connected, the system will begin operation in the dynamic pitch mode, the 0- 100 count range, and with the 99m Tc isotope selected.
Console display...
author: Shelley Holloway
|
|
|
DRAXIS Health Inc.
It is formulated as an easy-to-use lyophilized kit for reconstitution with Technetium-99m radioisotope, and is currently in the latter stages of two Phase III clinical trials in Canada and the United States.
INFECTON® is also formulated as an easy-to-use lyophilized kit for reconstitution with Technetium-99m and is under development and...
|
|
|
DRAXIS Health Inc.
INFECTON® is the proprietary combination of the widely used antibiotic, ciprofloxacin, with Technetium ( 99m Tc), the most commonly used radioisotope in nuclear medical imaging.
The INFECTON® kit for the preparation of 99m Tc-ciprofloxacin is a diagnostic radiopharmaceutical that has the potential to selectively distinguish infection...
|
|
|
DRAXIS Health Inc.
News Releases - - February 16, 2005 DRAXIS Diagnostic Radiopharmaceutical Approved in First European Country Approval in Netherlands for MAA diagnostic kit for lung imaging paves way for additional products and countries across Europe MISSISSAUGA, Ontario – February 16, 2005 – DRAXIS Health Inc.
(TSX: DAX; Nasdaq: DRAX) announced today that DRAXIMAGE, its...
|
|
|
Cytogen: ProstaScint Q&A for Doctors
site map contact us home SEARCH- ABOUT CYTOGEN PRODUCTS HEALT H CARE PROFESSIONAL Quadramet Information ProstaScint Information FAQs Clinical Pharmacology PIE™ Site Directory Reimbursement Information Prescribing Information Information Re quest Recent Publications Other Resources PATIENT RESOURCE CENTER PIPELINE INVESTOR RELATIONS NEWSROOM CAREERS LICENSING OPPORTUNITIES...
|
|
|
DRAXIS Health Inc.
News Releases - - January 9, 2003 DRAXIS to Initiate Phase I Clinical Testing of INFECTON Novel radiopharmaceutical designed for diagnostic imaging of infection MISSISSAUGA, Ontario - Januray 9, 2003 - DRAXIS Health Inc.
INFECTON is a radiopharmaceutical that has the potential to selectively distinguish infection from inflammation by binding directly with bacteria.
It combines...
|
|
|
DRAXIS Health Inc.
INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ( 99m Tc), the most commonly used radioisotope in nuclear medical imaging.
The INFECTON™ Kit for the preparation of 99m Tc-ciprofloxacin is a diagnostic radiopharmaceutical that has the potential to selectively distinguish infection from inflammation by binding...
|
|
|
DRAXIS Health Inc.
“The results of DRAXIMAGE’s investigation indicate that INFECTON ® should not be diluted after reconstitution to avoid any changes in the biodistribution pattern.” INFECTON ® combines the widely used antibiotic, ciprofloxacin, with Technetium ( 99m Tc), the most commonly used radioisotope in nuclear medical imaging.
Products currently...
|
|
|
DRAXIS Health Inc.
News Releases - - March 1, 2004 DRAXIS Approved to Market Skeletal Imaging Agent in USA MISSISSAUGA, Ontario, March 1, 2004 – DRAXIMAGE Inc., the radiopharmaceutical subsidiary of DRAXIS Health Inc.
The newly formulated diagnostic product, called MDP-25, is a kit for the preparation of Technetium Tc 99m Medronate Injection ( 99m Tc...
|
|
|
DRAXIS Health Inc.
INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ( 99m Tc), the most commonly used radioisotope in nuclear medical imaging.
The INFECTON™ Kit for the preparation of 99m Tc-ciprofloxacin is a diagnostic radiopharmaceutical that has the potential to selectively distinguish infection from inflammation by binding...
|
|
|
DRAXIS Health Inc.
“The results of DRAXIMAGE’s investigation indicate that INFECTON ® should not be diluted after reconstitution to avoid any changes in the biodistribution pattern.” INFECTON ® combines the widely used antibiotic, ciprofloxacin, with Technetium ( 99m Tc), the most commonly used radioisotope in nuclear medical imaging.
Products currently...
|
|
|
DRAXIS Health Inc.
News Releases - - March 13, 2002 DRAXIS Receives FDA Approval for In-house Manufacture of Lyophilized Products - - MISSISSAUGA, ONTARIO, March 13, 2002 - DRAXIS Health Inc.’s (TSE: DAX; NASDAQ: DRAX), radiopharmaceutical subsidiary, DRAXIMAGE Inc., has received U.S.
“In addition, with our own in-house lyophilization capability we are now positioned to respond to...
|
|
|
DRAXIS Health Inc.
News Releases - - January 9, 2003 DRAXIS to Initiate Phase I Clinical Testing of INFECTON Novel radiopharmaceutical designed for diagnostic imaging of infection MISSISSAUGA, Ontario – Januray 9, 2003 – DRAXIS Health Inc.
INFECTON is a radiopharmaceutical that has the potential to selectively distinguish infection from inflammation by binding directly with bacteria.
It...
|
|
|
3887_Draxis_cover&spine
Fibrimage ® is a product that links the radioactive isotope technetium- 99m (Tc- 99m) with the fibrin binding domain of human fibronectin, a recombinant polypeptide that has a high binding affinity for the primary component in an actively forming clot, or thrombus, which can form in the deep veins of the lower legs
INFECTON ® is a complex of Tc...
author: Charlyn Wee
|
